Differential Diagnoses for Chronic Large Bowel Diarrhea with Positive C. difficile GDH and Toxin

Primary Differential Considerations

The European Society of Clinical Microbiology and Infectious Diseases recommends that in a patient with chronic large bowel diarrhea and confirmed C. difficile infection, the primary differential is between true C. difficile infection versus C. difficile superimposed on underlying inflammatory bowel disease (IBD) 1, 2
The American Gastroenterological Association suggests that isolated CDI without underlying colonic pathology is the most straightforward diagnosis when both GDH and toxin are positive, with high specificity for active infection 3, 4
Clinical context is critical: recent antibiotic exposure, hospitalization history, fever, abdominal pain, and leukocytosis support true CDI, according to the Infectious Diseases Society of America 5
Approximately 81% of CDI cases respond to standard antibiotic therapy, suggesting isolated infection, as reported by the American College of Gastroenterology 6

The European Crohn’s and Colitis Organisation states that ulcerative colitis (UC) with C. difficile superinfection is a critical differential that significantly worsens outcomes 1, 2
UC patients with CDI have increased colectomy rates and postoperative complications compared to UC alone, according to the American Gastroenterological Association 1, 2

The Centers for Disease Control and Prevention recommends testing for Cytomegalovirus (CMV) in immunosuppressant-resistant UC, as it is associated with longer disease duration, reduced corticosteroid efficacy, and increased colectomy rates 1, 2
The World Health Organization suggests that Salmonella, Shigella, Campylobacter should be excluded through bacterial cultures, particularly in patients with colonic disease where diagnostic yield is higher 1, 2
The American Society of Tropical Medicine and Hygiene states that parasitic infections occur in approximately 12% of UC patients in endemic areas 1

The European Society of Clinical Microbiology and Infectious Diseases recommends colonoscopy as the modality of choice to assess for pseudomembranes and evaluate for underlying IBD pathology 1, 2
The American College of Gastroenterology suggests that histopathology can distinguish IBD-related inflammation from CDI-related changes 4

The Infectious Diseases Society of America advises against testing formed stool, as this results in false positives and unnecessary antibiotic therapy 5
The American Gastroenterological Association recommends against testing asymptomatic patients, as testing should be limited to symptomatic patients with ≥3 unformed stools in 24 hours 5
The European Crohn’s and Colitis Organisation suggests that if CDI treatment fails within 48-72 hours, colonoscopy and IBD-specific therapy should be pursued rather than prolonged CDI treatment 6